Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AEHAW NASDAQ:CALA NASDAQ:CLVR NASDAQ:SIOX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEHAWAesther Healthcare Acquisition$0.00$0.01$0.06▼$0.33N/AN/A34,287 shsN/ACALACalithera Biosciences$0.00$0.00$0.00▼$0.05N/A-2.8212,599 shs1,350 shsCLVRClever Leaves$0.00-99.2%$0.00$0.00▼$2.65N/A3440.041,724 shs2,684 shsSIOXSio Gene Therapies$0.48$0.46$0.25▼$0.50N/AN/AN/A40,403 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEHAWAesther Healthcare Acquisition0.00%-63.38%-74.00%-91.07%-98.37%CALACalithera Biosciences0.00%0.00%-95.00%-98.00%-99.50%CLVRClever Leaves-99.20%+100.00%-50.00%0.00%-99.99%SIOXSio Gene Therapies0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAEHAWAesther Healthcare AcquisitionN/AN/AN/AN/AN/AN/AN/AN/ACALACalithera BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ACLVRClever LeavesN/AN/AN/AN/AN/AN/AN/AN/ASIOXSio Gene TherapiesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEHAWAesther Healthcare Acquisition 0.00N/AN/AN/ACALACalithera Biosciences 0.00N/AN/AN/ACLVRClever Leaves 0.00N/AN/AN/ASIOXSio Gene Therapies 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEHAWAesther Healthcare AcquisitionN/AN/AN/AN/AN/AN/ACALACalithera BiosciencesN/AN/AN/AN/AN/AN/ACLVRClever Leaves$17.42M0.00N/AN/A$14.02 per share0.00SIOXSio Gene TherapiesN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEHAWAesther Healthcare AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/ACALACalithera Biosciences-$39.65MN/A0.00∞N/AN/AN/AN/AN/ACLVRClever Leaves-$17.90M-$11.31N/A∞N/AN/AN/AN/AN/ASIOXSio Gene Therapies-$71.89MN/A0.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAEHAWAesther Healthcare AcquisitionN/AN/AN/AN/AN/ACALACalithera BiosciencesN/AN/AN/AN/AN/ACLVRClever LeavesN/AN/AN/AN/AN/ASIOXSio Gene TherapiesN/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEHAWAesther Healthcare AcquisitionN/ACALACalithera BiosciencesN/ACLVRClever Leaves6.92%SIOXSio Gene TherapiesN/AInsider OwnershipCompanyInsider OwnershipAEHAWAesther Healthcare AcquisitionN/ACALACalithera Biosciences6.60%CLVRClever Leaves8.20%SIOXSio Gene Therapies3.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAEHAWAesther Healthcare Acquisition2N/AN/ANot OptionableCALACalithera Biosciences604.87 million4.55 millionNot OptionableCLVRClever Leaves5601.76 million1.61 millionNo DataSIOXSio Gene Therapies12N/AN/ANo DataSIOX, AEHAW, CALA, and CLVR HeadlinesRecent News About These CompaniesSio Gene Therapies Stock Price HistoryJune 3, 2025 | investing.comSio Gene Therapies Inc (OTC:SIOX) Stock Quotes, Forecast and News SummaryOctober 6, 2024 | benzinga.comOpportunity costs of gene therapies. Where do we go from here?August 25, 2024 | pharmaphorum.comPGene TherapyAugust 4, 2024 | ajmc.comALisa Jarvis: Would you get tested for an Alzheimer’s gene?May 13, 2024 | siouxcityjournal.comSCommercialization Strategies for Cell and Gene TherapiesMay 11, 2024 | fiercepharma.comFCell and Gene Therapy Diversity, Equity and InclusionMay 3, 2024 | bcm.eduBWalgreens expands specialty pharmacy and investment in gene therapyMay 1, 2024 | healthcarefinancenews.comHGene therapy and the germlineApril 22, 2024 | nature.comNGene Therapy for Parkinson's DiseaseMarch 31, 2024 | medscape.comMSio Gene Therapies, Inc. to File for Dissolution and Declare an Initial Liquidating Distribution of $0.435 Per ShareFebruary 2, 2024 | finance.yahoo.comSio Gene Therapies Inc SIOXNovember 22, 2023 | morningstar.comMTwo Promising Gene Therapy Stocks Tackling Eye DiseaseNovember 1, 2023 | thestreet.comGene Therapy News and ResearchOctober 28, 2023 | news-medical.netNGene Therapy for Erectile DysfunctionOctober 23, 2023 | medscape.comMIn Mice, Gene Therapy Helps Restore Movement After Spinal Cord InjurySeptember 27, 2023 | siouxcityjournal.comSRetroviral Vectors for Gene TherapySeptember 18, 2023 | medscape.comMSio Gene Therapies (NASDAQ: AXGT)July 19, 2023 | fool.comRoivant in Talks to Sell Stomach Drug to Roche in Deal Valued at More Than $7 BillionJuly 13, 2023 | finance.yahoo.comGene Therapy in a Patient with Sickle Cell DiseaseJune 20, 2023 | nejm.orgNTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack ModeSIOX, AEHAW, CALA, and CLVR Company DescriptionsAesther Healthcare Acquisition NASDAQ:AEHAW$0.0026 0.00 (0.00%) As of 07/14/2025Aesther Healthcare Acquisition Corp. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2021 and is based in New York, New York.Calithera Biosciences NASDAQ:CALA$0.0001 0.00 (0.00%) As of 07/14/2025 02:30 PM EasternCalithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.Clever Leaves NASDAQ:CLVR$0.0002 -0.02 (-99.20%) As of 07/15/2025 02:08 PM EasternClever Leaves Holdings Inc. operates in the botanical cannabinoid and nutraceutical industries. The company operates through two segments, Cannabinoid and Non-Cannabinoid. The Cannabinoid segment cultivates, extracts, manufactures, commercializes, and distributes cannabinoid products comprising cannabis flowers, cannabidiol isolates, full spectrum and standardized extracts, and dry smokable flowers internationally. The Non-Cannabinoid segment formulates, manufactures, markets, sells, distributes, and commercializes nutraceutical and other natural remedies, wellness products, detoxification products, and nutritional and dietary supplements for mass retailers, specialty and health retailers, and distributors in the United States. It also produces extracted products, including isolates, crude oil extracts, and oral solutions; and tetrahydrocannabinol flowers. The company serves retail distributors, pharmaceutical and cannabis companies, and pharmacies. Clever Leaves Holdings Inc. was founded in 2017 and is based in Tocancipá, Colombia.Sio Gene Therapies NASDAQ:SIOXSio Gene Therapies Inc., a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. It has a license agreement with Oxford BioMedica (UK) Ltd. to develop and commercialize AXO-Lenti-PD and related gene therapy products; and The University of Massachusetts Medical School to develop and commercialize gene therapy product candidates, including AXO-AAV-GM1 and AXO-AAV-GM. The company was formerly known as Axovant Gene Therapies Ltd. and changed its name to Sio Gene Therapies, Inc. in November 2020. Sio Gene Therapies, Inc. was incorporated in 2014 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings JPMorgan Q2 Results Affirm Dividend, Buybacks, & Growth NVDA Greenlight: China H20 Sales Spark 50% Rally Potential Tesla: 2 Plays Ahead of Next Week's Earnings Report New Catalyst Sends Joby Stock to 52-Week Highs Palantir Gets Price Hike From Wedbush Amid High Valuation Fastenal Surges After Earnings Beat, Tariff Risks Loom Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
